76Photo: IMS Advisory Council (IMAC) 2023August 22-24 in Yokohama. This meeting was important for several reasons: 1) The length of time since the last IMAC meet-ing was longer than usual. Due to the COVID-19 pandemic, this was the first evaluation of IMS since 2019. 2) This was the first opportunity to evaluate IMS for a full period following the 2018 completion of the merger of its components - the RIKEN Center for Genomic Medicine, the Research Center for Allergy and Im-munology, the Division of Genomic Technologies, and the Center for Life Science Technologies. 3) There will be a significant reor-ganization of the IMS research structure in the next term (2025-2032).The advisory council (AC) consisted of 18 renowned sci-ence leaders, 13 from overseas and five from Japan, chaired by Dr. Bernard Malissen (Marseille-Luminy, Marseille, France) and co-chaired by Dr. Mark Lathrop (McGill University, Montreal, Canada). The AC’s role is to provide an unbiased scientific evalu-ation of IMS and advice on future directions, as well as to support the IMS Director in research and personnel strategy decisions.On the first day, after Executive Director Miyazono provided an overview of RIKEN and Director Yamamoto introduced IMS, an outline of four new Pillars of Research for the next term was presented. The second day was dedicated to reviewing individual laboratories, which were arranged into six thematic groups and evaluated by three AC reviewers each. The third day included held on January 17, 2023 in a hybrid format at Station Conference Tokyo and online. A total of 351 participants were recorded, including guests from the Secretariat for Health and Medical Care Strategy Promotion of the Cabinet Office, the Min-istry of Education, Culture, Sports, Science and Technology, and the Japan Agency for Medical Research and Development.The theme of the symposium was “Integration of Data Science into Medical Sciences,” and discussions were held on the integra-tion of hypothesis-testing research that has been conducted so far in the biomedical sciences and data-driven research made possible by the rapid development of measurement technology in recent years.Three invited speakers, Dr. Stephen Quake (Professor at Stanford University, Head of Science at Chan Zuckerberg Initia-tive), Dr. Lude Franke (Professor at University of Groningen), Dr. Etsuo Susaki (Professor at Juntendo University) presented the latest findings of multi-omics research at the single cell, cohort, and spatial levels. The latest research being conducted at RIKEN a meeting with young IMS investigators and presentations on Future Plans and Governance. In the final session, Dr. Malissen summarized the overall findings of the IMAC review and the chair of each group provided further details. In a summary state-ment, they said: “The world-class quality of the Center’s research activities can be readily documented. The IMAC congratulates Director Yamamoto and all of the IMS members for their accom-plishments.” The complete public report is available on the IMS website: https://www.riken.jp/medialibrary/riken/about/reports/evaluation/ims/imac2023-report-e.pdfIMS in the areas of genome function, human immunity, disease systems, and cancer immunity was reported by Dr. Kazuhiko Ya-mamoto, Dr. Kazuyoshi Ishigaki, Dr. Yukinori Okada, Dr. Chung Chau Hon, Dr. Akihiko Koseki, and Dr. Hiroshi Ohno of RIKEN IMS. This information triggered lively discussions.IMS Advisory Council MeetingThe 2023 IMS Advisory Council (IMAC) meeting was held IMS SymposiumThe IMS Symposium, the first in five years since 2018, was
元のページ ../index.html#82